BE-595M Homework Assignment Due: 3/3/08

Size: px
Start display at page:

Download "BE-595M Homework Assignment Due: 3/3/08"

Transcription

1 BE-595M Homework Assignment Due: 3/3/08 Attached is a Warning Letter issued to Applied Water Engineering, Inc., Salt Lake City, UT, for violations of the Quality System Regulations. The firm manufactures the PA2000 and SPD reverse osmosis water purification systems for dialysis and the Bicarb Mixer. Referring to the attached Warning Letter: Choose 5 of the 11 cited Quality System regulation violations and explain the significance of the observation, i.e. how could the violation contribute to device defects/failures; how does the violation affect the overall product quality? The assignment may be submitted in hard copy or ed (mleal@wpi.edu) before the class on 3/3/08. Credit will be reduced on assignments received late.

2 DEPARTMENT OF HEALTH AND HUMAN SERVICES Southwest Region Food and Drug Administration Denver District Office Bldg. 20-Denver Federal Center P.O. Box ' Avenue & Kipling Street Denver, Colorado Telephone : 303" FAX: December 27, 2006 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED. " Mr. Stephen C. Carr President Applied Water Engineering, Inc South 300 West, Suite G Salt Lake City, Utah Ref # DEN Dear Mr. Carr : During an inspection of your firm located in Salt Lake City, Utah on July 11 through July 14, 2006, our investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the PA2000 and SPD reverse osmosis (RO) water purification systems -for dialysis, and the Bicarb Mixer. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or any function of the body. This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. 351(h)), in that the methods used in, or the facilities or controls used their for, manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) re,quirements of the Quality System (QS) regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. Significant violations include, but are not limited to, the following :. 1. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR (i). For example, design changes were not documented or reviewed for the -transformation of the older model (OFD). into the newer model known as the PA2000.

3 Page 2 - Applied Water Engineering, Inc., Salt Lake City, UT December 27 ; 2006 Change Order Procedure, approved. j(,. X_ x. only outlines the order process for replacement parts. This procedure does not address the requirements for design changes from the OFD model to the PA2000 model. Further, there was no evidence-of design validation or verification' or documentation of risk analysis prior to the implementation of design changes. 2. Failure to establish and maintain a design history file (DHF) for each type of device, as required by 21 CFR (j). For example, your firm lacked complete DHFs for both the SPD and the PA Failure to establish and maintain procedures for implementing corrective and preventive actions, including procedures for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of.nonconforming product, or other quality problems, as required by 21 CFR (a)(1). For example, your firm's procedures did not address the analysis of service repairs or defective component complaints.. 4. Failure to meet servicing requirements as specified at 21 CFR For example, customer service calls are not being adequately documented as required by 21 CFR (d). Your firm only maintains invoice records of parts sold to a customer and replacement parts sold to remedy a problem with a device.. Because your firm fails to adequately document service calls your firm is unable to determine if such calls represent an MDR reportable event that must be treated as a complaint and processed in accordance with the requirements of 21 CFR , as required by 21 CFR (c). 5. Failure to establish and maintain process control procedures that describe any process controls necessary to.ensure conformance to specifications such as documented instructions, standard operating procedures (SOPs), and methods that define and control the manner of production, as required by 21 CFR (a)(1). For example, your firm did not have any written assembly instructions or manufacturing procedures for the SPD or PA Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished.devices meets acceptance criteria, as required by 21 CFR (d). For example, a review of the acceptance activities revealed no documentation of your firm's finished device testing and there were no dates, results,.or verification of comp Teteness of DMRs associated with production testidg for the SPD or PA2000. Your firm manufactured and distributed >C 1 PA2000s and SC "- SPDs without any

4 Page 3 - Applied Water Engineering, Inc., Salt Lake City, UT December 27, 2006 signature release (i.e., the Device System Test Record contains a field for "Acceptance for Sale by :" and "Date", and were both left blank). 7. Failure to document training and ensure all personnel are trained to adequately perform :their assigned responsibilities, as required by 21 CFR (b). Your Training Documentation P'rocedure 1._ X~ _ X X j states, X' x. However, there was no documentation indicating that the full time employee who performs the manufacturing of your firm's devices and is the author of some of the device housing diagrams has received training. 8. Failure to establish and maintain procedures to ensure that the device history records (DHRs) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record (DMR) and the established quality system requirements of 21 CFR Part 820, as required by 21 CFR For example, your firm lacked documentation demonstrating that your devices were manufactured in accordance with established instructions, SOPs, or methods, In addition, your firm's DHRs lacked documentation specifying which parts were used to manufacture the PA2000 or the SPD devices in 2005 and Failure to establish and maintain an adequate organizational structure to ensure that devices are designed and produced in accordance with the established quality system requirements, as required by 21 CFR (b). For example, your firm had no documentation indicating that a management representative. has been appointed to ensure that quality system requirements will be met. 10. Failure of management with executive responsibility. to review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency according to established procedures and to document the dates and results of quality system reviews, as required by 21 CFR (c). For example, your firm had no procedures for management review and no documentation showing that management reviews have been conducted. 11 : Failure to establish and maintain procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR For example, your firm had no procedures for quality audits and no documentation showing that quality audits have been conducted.

5 ' Page 4 = Applied Water Engineering, Inc., Salt Lake City, UT December 27, Our inspection also revealed that your SPD, PA2000 and the Bicarb Mixer devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. 352(t)(2), in that your firm failed or refused to furnish material or information respecting these devices that is required by or under section 519 of the Act,, 21 U.S.C. 360i, and 21 C.F.R. Part 803 -Medical Device Reporting (MDR) regulation. Significant deviations include, but are not limited to, the following : 1. Failure to develop, maintain, and implement written MDR procedures, as required by 21 CFR Your firm's Complaint Handling Procedure, x x, contains references to MDR in X places ' >c >c, x However, your firm has not established a separate and complete procedure for MDR reporting and the references to MDR in >C >G fails to meet the requirements of 21 CFR For example,' X ~, does not piovide for effective identification of events that meet the criteria of MDR reporting. Section X of the SOP contains provisions for submitting MDRs to FDA when you become aware of an event involving death or serious injury. However, our MDR regulation indicates that manufacturers must also submit MDRs whenever they become aware of an event that reasonably suggests that their marketed device has malfunctioned and that the device or a similar device marketed by the firm would be likely to cause or contribute to a death or serious injury if the malfunction were to recur, 21 CFR As a device manufacturer, your firm must develop a comprehensive written MDR procedure that fully meets the requirements of 21 CFR In addition, your firm's procedure should address other specific MDR requirements as specified in 21 CFR Part 803 including, but not limited to, the requirements relating to : investigation of MDR reportable events (21 CFR (b)(3)) ; five-day MDR reports (21 CFR ), baseline MDR reports (21 CFR ), supplemental MDR reports (21 CFR ), when not to file an MDR report (21 CFR ), what information to include in an MDR report, i.e. MedWatch 3500A Reporting form (21 CFR ), MDR event file and record retention requirements (21 CFR ), and pertinent MDR definitions that are essential to determining when an event/complaint is an MDR reportable event (21 CFR 803.3). Our.inspection also revealed that the Bicarb Mixer is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section approved 515(a) of application for the Act, 21 an investigational US.C. 360e(a),. device or an. Act, 21 U.S.C. 360j(g). exemption (IDE) The device is also under section misbranded 520(g) of the under section 502(o) the Act, 21 U.S.C. 352(o), because you did not notify the agency of your intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. 360(k), is deemed satisfied when a PMA is pending before the agency, 21 CFR (b). The kind of information you need to submit in order to obtain approval or clearance for your device is described on the Internet at httn :// html. The FDA will evaluate.the information you submit and decide whether your product may be legally marketed.

6 Page 5 - Applied Water Engineering, Inc., Salt Lake City, UT. December 27, 2006 Additionally, your devices are also misbranded under section 502(o) the Act, 21 U.S.C. 352(o), because they are manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act ; 21 U.S.C. 360, and because the Bicarb Mixer was not included in a list required by section 510(j) of the Act, 21 U.S.C. 360(j). You should take prompt action to correct the violation(s) addressed in this letter. Failure to promptly correct these violation(s) may result in regulatory action being initiated by the Food and Drug Administration,without further notice. These actions include, but are not limited to, seizure, injunction,, and/or civil money penalties. Also, federal agencies are advised of the issuance of all Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, premarket approval applications for Class III devices to which the Quality System regulation deviations are reasonably related will not be approved until the violations have been corrected. Requests for Certificates to Foreign Governments will not be granted until the violations related to the subject devices have been corrected. Please notify this office in writing within fifteen (15) working days from the date you receive this letter of the specific steps you have taken to correct the noted violations, including an explanation of how you plan to prevent these violation(s), or similar violation(s), from occurring again. Include documentation of the corrective action you have taken. If your planned corrections will occur over t'irine, please include a timetable for implementation of those corrections. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Your response should be sent to : Food and Drug Administration, Denver District, P. O. Box 25087, Denver, CO , Attention : William H. Sherer ; Compliance Officer. If you have any questions about the content of this letter please contact Mr : Sherer at (303) Finally, you should know that this letter is not intended.to be an all-inclusive list of the violations at your facility. It is your responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter an d~in the Inspectional Observations, Form FDA 483 (FDA 483), issued at the closeout of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality assurance systems. You should investigate and determine the causes of the violations, and take prompt actions to correct the violations and to bring your products into compliance. B. Belinda Collins Denver District Director

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations 1 of 5 2/11/2014 11:24 AM Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Baxter

More information

WARNING LETTER CERTIFIED MAIL -~ Q December 14, 2005

WARNING LETTER CERTIFIED MAIL -~ Q December 14, 2005 -~ Q DEPARTMENT Or HEALTI-I A\D HUMAN SERVICES Public Health Service Food and Drug Administration Central Region Telephone (973) 526-6006 New Jersey District Waterview Corporate Center 10 Waterview Blvd.,

More information

AMENDED WARNING LETTER CIN

AMENDED WARNING LETTER CIN Department of Health and Human Services Public Health Service Food and Drug Administration Cincinnati District Office Central Region 6751 Steger Drive Cincinnati, OH 45237-3097 Telephone: (513) 679-2700

More information

:,-, WARNING LETTER. Mr. Jean Claude Mas Chief Executive Officer Poly Implants Protheses, Sa 337 Avenue De Bruxelles La Seyne, Sur Mer France

:,-, WARNING LETTER. Mr. Jean Claude Mas Chief Executive Officer Poly Implants Protheses, Sa 337 Avenue De Bruxelles La Seyne, Sur Mer France +., %- *: $1.,X,, *,+,,r + $, DEPARTMENT +, %, >,,, :,-, OF HEALTH & HUMAN SERVICES Public Health Service VIA FEDERAL EXPRESS ~ 22moo WARNING LETTER Mr. Jean Claude Mas Chief Executive Officer Poly Implants

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Inspections, Compliance, Enforcement, and Criminal Investigations Husain, Mustafa M, M.D. 23-Jul-08 Department of Health and Human Services Public Health Service Food and Drug Administration Center for

More information

Bristol Myers Squibb Holdings Pharma., Ltd.

Bristol Myers Squibb Holdings Pharma., Ltd. Bristol Myers Squibb Holdings Pharma., Ltd. Department of Health and Human Services Public Health Service Food and Drug Administration 466 Fernandez Juncos Avenue Puerta De Tierra San Juan, Puerto Rico

More information

: study utilizing trieib)(4) b)(4) I I""-", _

: study utilizing trieib)(4) b)(4) I I-, _ DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EXPRESS Sarah H. Lisanby, M.D. 1051

More information

950 t2.d Public Heallh Service

950 t2.d Public Heallh Service DEPARTMENT OF HEALTH & HUMAN SERVICES CERTIFIED MAIL RETURN RECEIPT REQUESTED 950 t2.d Public Heallh Service Food and Drug Administration Detroit District 300 River Place Suite 5900 Detroit, MI 48207 Telephone:

More information

FDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7

FDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7 FDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7 DISCLAIMER: This document was prepared by editing the converted PDF file supporting FDA's request to OMB for continuation of record

More information

WARNING LETTER VIA FEDERAL EXPRES S

WARNING LETTER VIA FEDERAL EXPRES S DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850 WARNING LETTER VIA FEDERAL EPRES S George W. LeMaitre Chairman

More information

Complaint Handling and Medical Device Reporting (MDRs)

Complaint Handling and Medical Device Reporting (MDRs) Complaint Handling and Medical Device Reporting (MDRs) FDA Small Business Regulatory Education for Industry (REdI) Bethesda, MD September 26, 2013 Andrew Xiao Consumer Safety Officer, Postmarket and Consumer

More information

WARNING LETTER. an both of which were sponsored by. (formerly ). The products

WARNING LETTER. an both of which were sponsored by. (formerly ). The products g5~5s c Public Health Service ' SLRV7CLS r r f+ ~1Mr~la DEPARTMENT OF HEALTH & HUMAN SERVICES DEC 2 1 2005 Food and Drug Administration 9200 Corporate Blvd. Rockville, Maryland 20850 WARNING LETTER Via

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Self-Identification of Generic Drug Facilities, Sites, and Organizations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions

More information

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 60-4 (v4 ( ~' DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service. Food and Drug Administration 9200 Corporate Boulevard el Rockville, Maryland 20850 MAY - 6 2008 VIA FEDERAL EXPRES S Merrill W.

More information

FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update

FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update Ginger M. Sykes Supervisory Consumer Safety Officer Salt Lake City Resident Post Office of Regulatory Affairs U.S. Food and

More information

2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations

2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations 2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and

More information

Medical Device Reporting for Manufacturers

Medical Device Reporting for Manufacturers Medical Device Reporting for Manufacturers DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration Medical Device Reporting for Manufacturers Prepared by Division of

More information

DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued on: August 5, 2008

DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued on: August 5, 2008 Draft Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and FDA Staff Humanitarian Device Exemption (HDE) Regulation: Questions and Answers DRAFT GUIDANCE This guidance

More information

SJN DO CB Field Alert Reports. Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office

SJN DO CB Field Alert Reports. Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office SJN DO CB Field Alert Reports Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office SJN DO Mission Assuring that safe and effective drugs are available to the public

More information

+.,m 7. yw ~ ~ & DEC FEDERAL EXPRESS

+.,m 7. yw ~ ~ & DEC FEDERAL EXPRESS +,*,s WC, ~ *4+ S* DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service, % %,+ 747 +,m 7 Food and Drug Administration 5 Jg FEDERAL EXPRESS 2088 Gaither Road Rockville MD 20850 yw ~ ~ & 4 DEC 21997

More information

Version 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements

Version 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements Version 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements The Principal Investigator of a study that is requesting an abbreviated IDE for use of a non-significant risk device must attest to the

More information

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4 JUL 1 3 2CG3 WARNING LETTER Food and Drug Administration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850

More information

Document issued on: July 8, 2010

Document issued on: July 8, 2010 Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and Food and Drug Administration Staff Humanitarian Device Exemption (HDE) Regulation: Questions and Answers Document

More information

Texas Department of State Health Services

Texas Department of State Health Services Texas Department of State Health Services DRUGS AND MEDICAL DEVICES GROUP WEB SITE: http://www.dshs.state.tx.us/dmd/ ISSUANCE OF CERTIFICATES OF FREE SALE AND SANITATION AND/OR CERTIFICATES OF ORIGIN AND

More information

Chapter 21. FDA Inspections

Chapter 21. FDA Inspections Chapter 21 FDA Inspections Jennifer M. Thomas & Douglas B. Farquhar 21:1 Role of Inspections 21:1.1 Overview 21:1.2 FDA s Reasons to Inspect 21:1.3 Potential Outcomes of Inspections 21:2 FDA Authority

More information

FDA Reauthorization Act of 2017 (FDARA)

FDA Reauthorization Act of 2017 (FDARA) FDA Reauthorization Act of 2017 (FDARA) April 4, 2018 PRESENTED BY: Jessica Ringel Counsel FDA & Life Sciences Practice Group King & Spalding LLP (202) 626-9259 jringel@kslaw.com FDA Reauthorization Act

More information

May 12, 2016 MEMORANDUM. Certain provisions of FSMA are already in effect, namely: Mandatory recall authority (FSMA 206).

May 12, 2016 MEMORANDUM. Certain provisions of FSMA are already in effect, namely: Mandatory recall authority (FSMA 206). L A W O F F I C E S 7 0 0 T H I R T E E N T H S T R E E T, N. W. S U I T E 1 2 0 0 W A S H I N G T O N, D. C. 2 0 0 0 5-5 9 2 9 ( 2 0 2 ) 7 3 7-5 6 0 0 F A C S I M I L E ( 2 0 2 ) 7 3 7-9 3 2 9 w w w.

More information

Connie Hoy October 2013

Connie Hoy October 2013 Connie Hoy October 2013 Warning letter issued to firm for complaint handling Failure to report within 30 days Failure to implement adequate procedures Failure to establish standard review process No procedure

More information

Postmarketing Drug Safety and Inspection Readiness

Postmarketing Drug Safety and Inspection Readiness Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration

More information

Complaints Investigation and Review. Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018

Complaints Investigation and Review. Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Complaints Investigation and Review Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does not represent

More information

PART 573 DEFECT AND NONCOMPLIANCE REPORTS. Nat l Highway Traffic Safety Admin., DOT 573.3

PART 573 DEFECT AND NONCOMPLIANCE REPORTS. Nat l Highway Traffic Safety Admin., DOT 573.3 Nat l Highway Traffic Safety Admin., DOT 573.3 (b) Accelerometer mounting in the thorax is the same as specified in 572.44(b). (c) Accelerometer mounting in the pelvis is the same as specified in 572.44(c).

More information

Medical Devices and Device-Led Combination Products; Voluntary Malfunction Summary

Medical Devices and Device-Led Combination Products; Voluntary Malfunction Summary This document is scheduled to be published in the Federal Register on 08/17/2018 and available online at https://federalregister.gov/d/2018-17770, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND

More information

Changes to QSR. The table below provides a history of changes to FDA s Quality System Regulation (QSR)

Changes to QSR. The table below provides a history of changes to FDA s Quality System Regulation (QSR) Changes to QSR The table below provides a history of changes to FDA s Quality System Regulation (QSR) The citation is to the Federal R: the first number is the volume, FR indicates the Federal Register,

More information

. s%rwcu ~,+ *+ % %vd3a 7 Food and Drug Administration. Center for Devices and

. s%rwcu ~,+ *+ % %vd3a 7 Food and Drug Administration. Center for Devices and * %. s%rwcu ~,+ *+ Jf ~ DEPARTMENT OF HEAITH & HUMAN SERVICIB Public Health Setvice z 2 4/5924 % % %vd3a 7 Food and Drug Administration. Center for Devices and Radiological 2098 Gaither Road Via Federal

More information

Contains Nonbinding Recommendations

Contains Nonbinding Recommendations Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers/Processors with Interest in Exporting to China: Guidance for Industry

More information

PREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK. Marian Boardley 2013

PREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK. Marian Boardley 2013 PREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK Marian Boardley 2013 APPLICABLE GMP S: DIETARY SUPPLEMENT LABS Subparts for laboratory operations and testing, 21 CFR 111 D Equipment

More information

H 7608 S T A T E O F R H O D E I S L A N D

H 7608 S T A T E O F R H O D E I S L A N D LC00 01 -- H 0 S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO HEALTH AND SAFETY -- THE CONSUMER PROTECTION IN EYE CARE ACT Introduced By: Representatives

More information

Center for Devices and Radiological Health; Medical Devices and Combination Products;

Center for Devices and Radiological Health; Medical Devices and Combination Products; This document is scheduled to be published in the Federal Register on 12/26/2017 and available online at https://federalregister.gov/d/2017-27650, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Chapter 48 - Bioresearch Monitoring

Chapter 48 - Bioresearch Monitoring COMPLIANCE GUIDANCE MANUAL Chapter 48 - Bioresearch Monitoring Subject SPONSORS, CONTRACT RESEARCH ORGANIZATIONS AND MONITORS Implementation Date February 21, 2001 Completion Date Continuing Product Codes

More information

The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements

The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements Beatrice Moreau Senior Regulatory Advisor Registrar Corp 144 Research Drive Hampton, Virginia USA 23666

More information

GAO MEDICAL DEVICES. Status of FDA s Program for Inspections by Accredited Organizations. Report to Congressional Committees

GAO MEDICAL DEVICES. Status of FDA s Program for Inspections by Accredited Organizations. Report to Congressional Committees GAO United States Government Accountability Office Report to Congressional Committees January 2007 MEDICAL DEVICES Status of FDA s Program for Inspections by Accredited Organizations GAO-07-157 Accountability

More information

FSMA User Guide. Food Safety Modernization Act Guide

FSMA User Guide. Food Safety Modernization Act Guide Food Safety Modernization Act Guide The Food Safety Modernization Act of 2011 (FSMA), the first major overhaul of food safety legislation in more than 70 years, gives FDA the new job of building a modern,

More information

FISCAL YEAR FAMILY SELF-SUFFICIENCY PROGRAM GRANT AGREEMENT (Attachment to Form HUD-1044) ARTICLE I: BASIC GRANT INFORMATION AND REQUIREMENTS

FISCAL YEAR FAMILY SELF-SUFFICIENCY PROGRAM GRANT AGREEMENT (Attachment to Form HUD-1044) ARTICLE I: BASIC GRANT INFORMATION AND REQUIREMENTS 1 1 1 1 1 1 1 1 0 1 0 1 0 1 0 1 FISCAL YEAR 01 FAMILY SELF-SUFFICIENCY PROGRAM GRANT AGREEMENT (Attachment to Form HUD-) ARTICLE I: BASIC GRANT INFORMATION AND REQUIREMENTS 1. This Agreement is between

More information

Are You Ready for FSMA? Janet Raddatz VP Quality & Food Safety Systems Sargento Foods Inc. WAFP June 12, 2013

Are You Ready for FSMA? Janet Raddatz VP Quality & Food Safety Systems Sargento Foods Inc. WAFP June 12, 2013 Are You Ready for FSMA? Janet Raddatz VP Quality & Food Safety Systems Sargento Foods Inc. WAFP June 12, 2013 New Responsibilities for Food Companies Impacting daily operations in all registered facilities,

More information

DEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice WARNING LETTER

DEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice WARNING LETTER DEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice Food and Drug Administration 9200 CCorporate Bl%d. RockOlc MD 20550 WARNING LETTER VIA FEDERAL EXPRESS MP 4 2007 William D. Tobler, MD Mayfield

More information

Investigator Roles and Responsibilities in Clinical Device Trials

Investigator Roles and Responsibilities in Clinical Device Trials Investigator Roles and Responsibilities in Clinical Device Trials A Total Product Lifecycle Approach to Medical Device Development: Responsibilities and Opportunities The Stanford Center for Clinical and

More information

247 CMR: BOARD OF REGISTRATION IN PHARMACY 247 CMR 21.00: REGISTRATION OF OUTSOURCING FACILITIES. Section

247 CMR: BOARD OF REGISTRATION IN PHARMACY 247 CMR 21.00: REGISTRATION OF OUTSOURCING FACILITIES. Section 247 CMR 21.00: REGISTRATION OF OUTSOURCING FACILITIES Section 21.01: Purpose 21.02: Outsourcing Facility Registration Requirements 21.03: Provisional Outsourcing Facility Registration Requirements 21.04:

More information

FDA Medical Device Regulations vs. ISO 14155

FDA Medical Device Regulations vs. ISO 14155 Vol. 11, No. 9, September 2015 Happy Trials to You FDA Medical Device Regulations vs. ISO 14155 By Shawn Kennedy Medical device clinical trials must comply with 21 CFR Parts 11 (Electronic Records), 50

More information

Medicare Part C Medical Coverage Policy

Medicare Part C Medical Coverage Policy Clinical Trial Services Origination: June 28, 1999 Review Date: April 18, 2018 Next Review: April, 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE Clinical trials (or clinical research

More information

Regulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center

Regulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center Regulatory,Quality & Emergency Preparedness MaryBeth Parache Director, Quality Affairs New York Blood Center 1 Regulatory 2 Who regulates us? Food and Drug Administration (FDA) Blood, tissue, HCT/P, medical

More information

Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1

Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Donald D. Ashley, JD 2017 FDLI Enforcement, Litigation, and Compliance Conference: For the Drug,

More information

Received an RTA Deficiency List or AI Letter? Now What?

Received an RTA Deficiency List or AI Letter? Now What? Received an RTA Deficiency List or AI Letter? Now What? Dealing with Unexpected Issues/Questions during the Submission Review Process Navigating Submission Challenges to reduce time & risk September 26,

More information

DPAS Defense Priorities & Allocations System for the Contractor

DPAS Defense Priorities & Allocations System for the Contractor DPAS Defense Priorities & Allocations System for the Contractor Presented By: DCMA E&A Manufacturing and Production March 2014 Thursday, June 11, 2015 1 DPAS for the CONTRACTOR Any person who places or

More information

Hyundai Motor America, Receipt of Petition for Decision of. AGENCY: National Highway Traffic Safety Administration (NHTSA),

Hyundai Motor America, Receipt of Petition for Decision of. AGENCY: National Highway Traffic Safety Administration (NHTSA), This document is scheduled to be published in the Federal Register on 04/07/2017 and available online at https://federalregister.gov/d/2017-06954, and on FDsys.gov DEPARTMENT OF TRANSPORTATION National

More information

Contains Nonbinding Recommendations. Draft Not for Implementation

Contains Nonbinding Recommendations. Draft Not for Implementation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Public Notification of Emerging Postmarket Medical Device Signals ( Emerging Signals ) Draft Guidance for Industry

More information

Department of Transportation. National Highway Traffic Safety Administration. [Docket No. NHTSA ; Notice 1]

Department of Transportation. National Highway Traffic Safety Administration. [Docket No. NHTSA ; Notice 1] This document is scheduled to be published in the Federal Register on 09/28/2012 and available online at http://federalregister.gov/a/2012-23834, and on FDsys.gov Department of Transportation National

More information

DRAFT. (Industry Name) (Industry Address) (Industry Address) (SIC NUMBER (S))

DRAFT. (Industry Name) (Industry Address) (Industry Address) (SIC NUMBER (S)) REGULATED INDUSTRIAL WASTEWATER DISCHARGE PERMIT PERMIT NO. In compliance with the existing provisions of the City of Columbia Code of Ordinances, the Federal Clean Water Act (PL 95-217) and the General

More information

KDOT Procurement Guidelines for STP/CMAQ Funded Planning, Education, and Outreach Projects Effective 10/1/12

KDOT Procurement Guidelines for STP/CMAQ Funded Planning, Education, and Outreach Projects Effective 10/1/12 KDOT Procurement Guidelines for STP/CMAQ Funded Planning, Education, and Outreach Projects Effective 10/1/12 Purpose These guidelines are intended to guide the procurement of goods and consultant services

More information

STUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)

STUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both

More information

Family Child Care Licensing Manual (November 2016)

Family Child Care Licensing Manual (November 2016) Family Child Care Licensing Manual for use with COMAR 13A.15 Family Child Care (as amended effective 7/20/15) Table of Contents COMAR 13A.15.13 INSPECTIONS, COMPLAINTS, AND ENFORCEMENT.01 Inspections...1.02

More information

Re: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products

Re: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products March 13, 2014 BY ELECTRONIC DELIVERY Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental

More information

Dr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015

Dr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015 18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL

More information

Case: 1:10-cv Document #: 74-1 Filed: 04/15/11 Page 1 of 7 PageID #:2403 EXHIBIT A

Case: 1:10-cv Document #: 74-1 Filed: 04/15/11 Page 1 of 7 PageID #:2403 EXHIBIT A Case: 1:10-cv-06016 Document #: 74-1 Filed: 04/15/11 Page 1 of 7 PageID #:2403 EXHIBIT A Case: 1:10-cv-06016 Document #: 74-1 Filed: 04/15/11 Page 2 of 7 PageID #:2404 UNITED STATES DISTRICT COURT NORTHERN

More information

10/4/12. Controlled Substances Dispensing Issues and Solutions. Objectives. Financial Disclosure

10/4/12. Controlled Substances Dispensing Issues and Solutions. Objectives. Financial Disclosure Controlled Substances Dispensing Issues and Solutions Ronald W. Buzzeo, R.Ph. Chief Compliance Officer November 7, 2012 CE Code: Financial Disclosure I have no actual or potentially relevant financial

More information

Environmental Management Chapter ALABAMA DEPARTMENT OF ENVIRONMENTAL MANAGEMENT WATER DIVISION - WATER SUPPLY PROGRAM ADMINISTRATIVE CODE

Environmental Management Chapter ALABAMA DEPARTMENT OF ENVIRONMENTAL MANAGEMENT WATER DIVISION - WATER SUPPLY PROGRAM ADMINISTRATIVE CODE Environmental Management Chapter 335-7-4 ALABAMA DEPARTMENT OF ENVIRONMENTAL MANAGEMENT WATER DIVISION - WATER SUPPLY PROGRAM ADMINISTRATIVE CODE CHAPTER 335-7-4 PERMIT REQUIREMENTS AND PROCEDURES TABLE

More information

Establishment Registration and Device Listing. Michelle C. Jackson, Esq. Partner Venable LLP

Establishment Registration and Device Listing. Michelle C. Jackson, Esq. Partner Venable LLP Establishment Registration and Device Listing Michelle C. Jackson, Esq. Partner Venable LLP Learning Objectives Statutory Basis for Registration and Listing Relevant Regulations Who Must Register and List

More information

twj arid Cltug AJmiist : a tuxt --.,~ 9200 (:wpcuat : IlkJ Ko:.l, v ille A4Il

twj arid Cltug AJmiist : a tuxt --.,~ 9200 (:wpcuat : IlkJ Ko:.l, v ille A4Il 5~ := DEPARTMENT OF HEALTH & HUMAN SERVICE S.'' P116 :1, I Ir31th Serrsc e twj arid Cltug AJmiist : a tuxt --.,~ 9200 (:wpcuat : IlkJ Ko:.l, v ille A4Il 2085 0 2 6 L ~l! WARNING LETTER Via Federal Express

More information

ASSEMBLY, No STATE OF NEW JERSEY. 214th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 2010 SESSION

ASSEMBLY, No STATE OF NEW JERSEY. 214th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 2010 SESSION ASSEMBLY, No. STATE OF NEW JERSEY th LEGISLATURE PRE-FILED FOR INTRODUCTION IN THE 0 SESSION Sponsored by: Assemblyman FREDERICK SCALERA District (Bergen, Essex and Passaic) Assemblywoman LINDA R. GREENSTEIN

More information

I. NPDES Permits BUREAU OF MINING PROGRAMS

I. NPDES Permits BUREAU OF MINING PROGRAMS BUREAU OF MINING PROGRAMS Standard Operating Procedure (SOP) 1 for District Mining Operations Enforcing NPDES Permit Requirements for Mining Operations SOP No. BMP-004 The NPDES program for mining is implemented

More information

always legally required to follow the privacy practices described in this Notice.

always legally required to follow the privacy practices described in this Notice. The ANXIETY & STRESS MANAGEMENT INSTITUTE 1640 Powers Ferry Rd, Building 9, Suite 10 0, Marietta, Georgia 30067, 770-953-0080 Health Insurance Portability and Accountability Act (HIPAA) NOTICE OF PRIVACY

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Inspections, Compliance, Enforcement, and Criminal Investigations Dallas Jr, Anthony V, MD 11/09/09 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,

More information

Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA

Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this

More information

Drug and Medical Device Registration FAQ

Drug and Medical Device Registration FAQ Drug and Medical Device Registration FAQ Contents Types of Submissions... 3 When is it appropriate to submit a new application form F-2?... 3 Do I need to submit a new application for a new or changed

More information

DEPUTY SECRETARY OF DEFENSE 1010 DEFENSE PENTAGON WASHINGTON, D.C

DEPUTY SECRETARY OF DEFENSE 1010 DEFENSE PENTAGON WASHINGTON, D.C DEPUTY SECRETARY OF DEFENSE 1010 DEFENSE PENTAGON WASHINGTON, D.C. 20301-1010 June 17, 2009 Incorporating Change 6, effective September 10, 2015 MEMORANDUM FOR SECRETARIES OF THE MILITARY DEPARTMENTS CHAIRMAN

More information

Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission

Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission This document is scheduled to be published in the Federal Register on 06/07/2018 and available online at https://federalregister.gov/d/2018-12223, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

IMPORTANT NOTICE PLEASE READ CAREFULLY SENT VIA FEDEX AND INTERNET

IMPORTANT NOTICE PLEASE READ CAREFULLY SENT VIA FEDEX AND INTERNET Department of Health & Human Services Centers for Medicare & Medicaid Services 61 Forsyth Street, SW, Suite 4T20 Atlanta, Georgia 30303-8909 Refer to: 5213.abIJ.06.27.18. docx ` June 27, 2018 IMPORTANT

More information

Medical Device Reporting. FD&C Act CFR Direct Final Rule 2/28/05. As amended by:

Medical Device Reporting. FD&C Act CFR Direct Final Rule 2/28/05. As amended by: Medical Device Reporting Direct Final Rule 2/28/05 FD&C Act 519 As amended by: Safe Medical Devices Act of 1990 Medical Device Amendments of 1992 FDA Modernization Act of 1997 Authority to require manufacturers,

More information

Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements

Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements Guidance for Industry and FDA Staff Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements Document Issued on: February 28, 2008

More information

Medical Devices: Do I Need to Open a CAPA?

Medical Devices: Do I Need to Open a CAPA? Medical Devices: Do I Need to Open a CAPA? Adrienne Franco Busby, Partner, Faegre Baker Daniels LLP Anne Miller, Principal Regulatory Counsel, Medtronic Marta L. Villarraga, Principal, Exponent, Inc. Moderated

More information

A Better You Counseling Services, LLC 1225 Johnson Ferry Road, Ste 170 Marietta GA

A Better You Counseling Services, LLC 1225 Johnson Ferry Road, Ste 170 Marietta GA A Better You Counseling Services, LLC 1225 Johnson Ferry Road, Ste 170 Marietta GA 30068 404-216-1135 Health Insurance Portability and Accountability Act (HIPAA) NOTICE OF PRIVACY PRACTICES I. COMMITMENT

More information

MDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review

MDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review Page 1 MDUFA Performance Goals and Procedures... 3 I. Process Improvements... 3 A. Pre-Submissions... 3 B. Submission Acceptance Criteria... 4 C. Interactive Review... 5 D. Guidance Document Development...

More information

Regulatory Affairs Outsourcing

Regulatory Affairs Outsourcing Regulatory Affairs Outsourcing INTRODUCTION The FDA Group, LLC (The FDA Group) is an organization that utilizes a proprietary talent selection process of former FDA & industry professionals, amplified

More information

BIMO SITE AUDIT CHECKLIST

BIMO SITE AUDIT CHECKLIST Item AUTHORITY AND ADMINISTRATION FOR STUDIES INVOLVING HUMAN DRUGS, BIOLOGICS AND DEVICES 1. Compare the Investigator Agreement with the information provided by the assigning Center. Auditor will check

More information

Regulations for the Supervision and Administration. of Medical Devices

Regulations for the Supervision and Administration. of Medical Devices Regulations for the Supervision and Administration Article 1 of Medical Devices Chapter I General Provisions These Regulations are formulated with a view to ensuring the safety and effectiveness of medical

More information

IMPORTANT NOTICE PLEASE READ CAREFULLY SENT VIA FEDEX AND INTERNET (Receipt of this notice is presumed to be May 7, 2018 date notice ed)

IMPORTANT NOTICE PLEASE READ CAREFULLY SENT VIA FEDEX AND INTERNET  (Receipt of this notice is presumed to be May 7, 2018 date notice  ed) Department of Health & Human Services Centers for Medicare & Medicaid Services 61 Forsyth Street, SW, Suite 4T20 Atlanta, Georgia 30303-8909 ` Refer to: 34-5529.NOTC.G.05.07.18.docx IMPORTANT NOTICE PLEASE

More information

Agency for Health Care Administration

Agency for Health Care Administration Page 1 of 13 ST - P0000 - Initial Comments Title Initial Comments Statute or Rule Type Memo Tag ST - P0102 - Registration Changes Title Registration Changes Statute or Rule 400.980(2) FS; 59A-27.002(1)

More information

REVISION: This revised Management Directive (MD) updates TSA MD , dated January 29, 2004.

REVISION: This revised Management Directive (MD) updates TSA MD , dated January 29, 2004. OFFICE OF OCCUPATIONAL SAFETY, HEALTH, AND ENVIRONMENT TSA MANAGEMENT DIRECTIVE No. 2400.3 REVISION: This revised Management Directive (MD) updates TSA MD 2400.3, dated January 29, 2004. SUMMARY OF CHANGES:

More information

CHAPTER FIFTEEN- NEGATIVE ACTIONS

CHAPTER FIFTEEN- NEGATIVE ACTIONS CHAPTER FIFTEEN- NEGATIVE ACTIONS I. Statutory Authority SC Statute 63-13-460 a. License Denial; nonrenewal; notice; hearing; appeals (A) An applicant who has been denied a license by the department must

More information

Food Safety Modernization Act (FSMA)

Food Safety Modernization Act (FSMA) Food Safety Modernization Act (FSMA) FDA FSMA Timeline July 29, 2009 House version passed Votes 283-142 Nov. 30, 2010 Senate version passed Votes 73-25 Dec. 19, 2010 Senate revised version passed Unanimous

More information

Administrative Policies and Procedures. Policy No.: N/A Title: Medical Equipment Management Plan

Administrative Policies and Procedures. Policy No.: N/A Title: Medical Equipment Management Plan Administrative Policies and Procedures Originating Venue: Environment of Care Title: Medical Equipment Management Plan Cross Reference: Date Issued: 11/14 Date Reviewed: Date: Revised: Attachment: Page

More information

Department of Defense INSTRUCTION

Department of Defense INSTRUCTION Department of Defense INSTRUCTION NUMBER 4715.6 April 24, 1996 USD(A&T) SUBJECT: Environmental Compliance References: (a) DoD Instruction 4120.14, "Environmental Pollution Prevention, Control and Abatement,"

More information

Pharmaceutical Services Requirements: formerly 10D and 10C.7

Pharmaceutical Services Requirements: formerly 10D and 10C.7 Pharmaceutical Services Requirements: formerly 10D.28-29 and 10C.7 Frank S. Emanuel, Pharm.D., FASHP Associate Professor/Division Director Florida A and M University College of Pharmacy Jacksonville Disclosure

More information

DEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter,

DEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter, DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Ronald Bukowski, M.D. 28099 Gates Mills

More information

North Carolina Community College System Office Apprenticeship and Training Bureau 200 W. Jones Street Raleigh, NC 27603

North Carolina Community College System Office Apprenticeship and Training Bureau 200 W. Jones Street Raleigh, NC 27603 STATE BOARD OF COMMUNITY COLLEGES RATIFICATION OF TITLE 4, CHAPTER 22 OF THE NORTH CAROLINA ADMINISTRATIVE CODE APPRENTICESHIP AND TRAINING DIVISION Section 15.13.(a) of Session Law 2017-57 transfers the

More information

REQUEST FOR PROPOSAL (RFP) PROJECT MANAGEMENT CEDAR BAND TRAVEL PLAZA ENTERPRISE

REQUEST FOR PROPOSAL (RFP) PROJECT MANAGEMENT CEDAR BAND TRAVEL PLAZA ENTERPRISE REQUEST FOR PROPOSAL (RFP) PROJECT MANAGEMENT CEDAR BAND TRAVEL PLAZA ENTERPRISE PAIUTE INDIAN TRIBE OF UTAH 440 NORTH PAIUTE DRIVE CEDAR CITY, UT 84721 OCTOBER 18, 2017 TABLE OF CONTENTS 1. SUMMARY AND

More information

Teaching Institution Application for Registration (Form DHHS 224-C)

Teaching Institution Application for Registration (Form DHHS 224-C) Teaching Institution Application for Registration (Form DHHS 224-C) NC Department of Health and Human Services Division of Mental Health, Developmental Disabilities, and Substance Abuse Services Drug Control

More information

Standard Operating Procedures

Standard Operating Procedures Clinical Monitoring and Site Verification Procedure Overview To define the standard procedures for preparation and documentation of site visits for clinical monitoring and spoke verification for any NETT

More information

**IF YOU SHOW UP WITHOUT ANY OF THE LISTED ITEMS, WE WILL RESCHEDULE!!!**

**IF YOU SHOW UP WITHOUT ANY OF THE LISTED ITEMS, WE WILL RESCHEDULE!!!** Dr. Jasna Kojic 6000 Turkey Lake Rd. Suite 205 Orlando, FL 32819 PHONE: (407) 649-1848 FAX: (407) 649-1979 Dear Parent/Guardian of : We welcome you and your son/daughter to our office and are happy to

More information

Executive Summary 56,173 Purpose and Coverage of the Rule 56,173 Summary of the Major Provisions of the Rule 56,173 Costs and Benefits 56,175

Executive Summary 56,173 Purpose and Coverage of the Rule 56,173 Summary of the Major Provisions of the Rule 56,173 Costs and Benefits 56,175 Executive Summary 56,173 Purpose and Coverage of the Rule 56,173 Summary of the Major Provisions of the Rule 56,173 Costs and Benefits 56,175 I. Background 56,176 A. FDA Food Safety Modernization Act 56,176

More information

Protecting, Maintaining and Improving the Health of Minnesotans

Protecting, Maintaining and Improving the Health of Minnesotans CMS Certification Number (CCN): 245210 Delivered electronically September 25, 2014 Mr. Rob Lahammer, Administrator Lake Minnetonka Shores 4527 Shoreline Drive Spring Park, Minnesota 55384 Protecting, Maintaining

More information